High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL

Blinatumomab is a bispecific T-cell engager approved for B-cell precursor acute lymphoblastic leukemia (B-ALL) with persistent minimal residual disease (MRD) or in relapse. The prognostic impact of tumor load has been suggested before other immunotherapies but remains poorly explored before blinatum...

Descripción completa

Detalles Bibliográficos
Autores principales: Cabannes-Hamy, Aurélie, Brissot, Eolia, Leguay, Thibaut, Huguet, Françoise, Chevallier, Patrice, Hunault, Mathilde, Escoffre-Barbe, Martine, Cluzeau, Thomas, Balsat, Marie, Nguyen, Stéphanie, Pasquier, Florence, Alexis, Magda, Lhéritier, Véronique, Pastoret, Cédric, Delabesse, Eric, Clappier, Emmanuelle, Dombret, Hervé, Boissel, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article - Acute Lymphoblastic Leukemia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425331/
https://www.ncbi.nlm.nih.gov/pubmed/35263986
http://dx.doi.org/10.3324/haematol.2021.280078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425331/
https://www.ncbi.nlm.nih.gov/pubmed/35263986
http://dx.doi.org/10.3324/haematol.2021.280078

Ejemplares similares